[company_age]8.0[/company_age][employees]11-50 employees[/employees][funding]Series unknown[/funding][description]Genome Biologics is a biotechnology company specializing in the development of therapies for cardiovascular and cardiometabolic diseases. The company leverages its proprietary AI-driven preclinical multi-modality drug testing technology to identify viable drug candidates and FDA-approved drug repositioning compounds. Genome Biologics' technology platform seamlessly integrates Ai-driven big data analysis with precision preclinical organoid (TrueCardium™) and in vivo disease models for therapeutic validation. This synergistic workflow expedites drug discovery and development, reducing the cost, time, and ethical burden of preclinical research. The company has a rich therapy pipeline in Cardiotoxicity, Heart failure, and Hypertrophic cardiomyopathy, employing strategies such as cellular metabolic modulation and the reactivation of cardiac regeneration. Genome Biologics is a resident company of Johnson & Johnson Innovation - JLABS, a premier life science incubator program, and has received the European Union H2020 SME Instrument Phase 1 and 2 award.[/description][ps]Therapeutic drug candidates for cardiovascular and cardiometabolic diseases[/ps]